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Motivation of the paper
 To explore how scientists’ brokerage positions facilitates their participation in
different activities related to medical innovation.
 To analyze whether different brokerage roles are equally effective in facilitating
the scientists’ engagement in a range of medical innovation activities.
 To explore whether brokerage positions operate differently if the institutional
context of the focal scientist is taken into account.
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 The biomedical context is composed by many institutionalized occupational boundaries that
have a diversity of characteristics and interests (Currie et al., 2012). (e.g.: basic scientists, clinical
scientists, practitioners, patients).
 Need to reduce distance between these actors as a way to translate knowledge “from the
bench to the bedside” (Marincola, 2003)
 Thus, “brokers” or “connectors” are critical to translate and coordinate knowledge and
interests between disparate communities, as a way to accelerate the diffusion of basic
research evidence into clinical practice (Waring et al., 2013).
Knowledge brokerage in the biomedical context
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Background: medical innovation and network brokerage
Knowledge brokerage: definition
In network research, a brokerage position is characterized by the absence of ties
between the contacts of a focal actor.
Formally, a knowledge broker (A) is a focal actor who mediates the flow of knowledge
between two other unconnected actors (Burt, 1992, Wasserman & Faust, 1994). Knowledge and
resources between B and C only flow through A.
A
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Background: medical innovation and network brokerage
What is behind the network advantage
Network theory predicts that knowledge brokers’ advantage come in two forms:
 An information advantage. Being a broker provides more opportunities to:
- …tap into diverse knowledge
- …spot similarities between unrelated knowledge
- …synthesize contradictory points of view
- …come up with novel ideas
 brokers are in a better position to innovate
 A timing advantage. Brokers have a faster access to new knowledge (Burt, 1997, 2007).
Therefore, where timing is rewarded, a brokerage position may provide a crucial advantage.
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Network brokerage and medical innovation
 Holding brokerage positions also entails coordination and cognitive costs for the focal
actor:
The dark side of brokerage positions
Coordination costs Cognitive costs
Coordination costs accrue from the structure
of the network (keeping and maintaining a
large set of unconnected contacts)
Cognitive costs accrue from the content of
the network (dealing with an overload of
disparate knowledge and interests)
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Maintaining a too large set of brokerage positions
may distract the focal actor to engage in other
activities that may be also crucial to innovate (Perry-
Smith & Shalley, 2003).
A large set of unconnected contacts undermines
the creation of trust between the network
members and thus, hinders the transfer of tacit
knowledge (Coleman, 1998, Hansen, 1999)
When the number of ties is too large, individuals
are likely to experience information overload: They
may be unable to cope with voluminous and
discordant information (Zhou et al. 2009)
Sparse networks are formed by diverse people that
are inherently more difficult to mobilize or
coordinate, due to disparate interests, perspectives
and languages.
Brokerage roles and medical innovation 
 To better understand the link between brokerage positions and medical innovation, we propose
to analytically decompose brokerage positions into different types, based on the type of actors
each node is connected to (Gould & Fernandez, 1989).
Ego
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Liaison Gatekeeper Consultant Coordinator
*Colours represent different institutional affiliations or professional groups
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brokerage roles
Knowledge diversity Cognitive costs Coordination  costs
Liaison High High constant
Gatekeeper Medium Medium constant
Consultant Medium Medium constant
Coordinator Low Low constant
 The potential benefits and costs of brokerage partly depend on the diversity of actors
involved in the relationship.
 Being a liaison means that the broker is an outsider with respect to both contacts he is linking. The actor’s role
is to link different groups. That means: greater opportunities to obtain heterogeneous knowledge.
However, it also requires greater cognitive efforts to integrate and coordinate the disparity of interests.
 Being a coodinator means that all actors belong to the same group, so the brokerage relation is completely
internal. That implies:
 Lower access to heterogeneous perspectives.
 Lower coordination costs.
 We expect different brokerage roles having distinct effects on medical innovation
Distinctive effects of brokerage roles on medical innovation
Higher knowledge
diversity
Lower knowledge
diversity
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 Cognitive costs depend on the brokerage role played by each actor. Coordination costs arise irrespective of the
brokerage role, because they arise from the structure of the ego-network.
 Gatekeeper positions will provide the greater balance between benefits and costs of
brokerage. Thus, gatekeeper positions will be more strongly associated to the scientists’
participation in a range of medical innovation activities, compared to other positions.
Hypothesis 1: There is a positive association between holding gatekeeper positions and 
participating in medical innovation activities.
 Occupying coordinator positions will be the less effective brokerage role in predicting the
scientists’ participation in medical innovation activities, because it provides the lower
access to heterogeneous actors.
Distinctive effects of brokerage roles: hypotheses
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The influence of the institutional context
 Network studies have provided growing empirical evidence on the importance of
brokerage. However, scarce attention has been given to the institutional and
organizational context where social interactions take place (Pachucki & Brieger 2010).
 We know that the institutional settings where scientists work present distinctive goals,
values, incentive structuresand cultural norms (Dasgupta & David 1994, Whitley 2000)
 In hospital settings the participation in medical innovation activities is partly embedded
in the values and institutional norms. Moreover, access to critical contacts and resources
to do so might be more easily found inside the institution.
Hypothesis 2: Working in hospital settings weakens the positive connection between
gatekeeper positions and participation in medical innovation activities.
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Spanish Biomedical Research Networking Centers (CIBERs) are formal networks structures
created by the Spanish Ministry of Health in 2007.
Aims of the CIBER networks:
 Bring together scientists from universities, hospitals and research centers working on similar
fields.
 Organize biomedical research around nine pathologies of critical interest for the Spanish’
National Health System:
 Neurodegenerative diseases
 Rare diseases
 Hepatic diseases
 Bioengineering, Biomaterials and Nanomedicine
 Epidemiology and Public Health
 Obesity and Nutrition
 Respiratory Diseases
 Mental Health
 Diabetes and Metabolic Associated Diseases
Research context and methods
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Research context and methods (ii)
Sample frame for the study:
All biomedical scientists and technicians belonging to each of the nine CIBER networks (4,758
individuals).
Implementation of a survey
We designed a questionnaire to identify each scientist’ collaborative network (external to
his/her research team), their individual attributes and their degree of engagement in multiple
activities related to medical innovation.
Overall response rate = 28 % (1,309 valid responses)
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Items
Patent applications for new drugs
Granted licenses from patents
Participation in spin-off
Clinical trials phases I, II or III for new drugs development
Clinical trials phase IV for new drugs development
Clinical trials phase IV for new diagnostic techniques
Clinical guidelines for healthcare professionals
Clinical guidelines for patients
Patent applications for new diagnostic techniques
Clinical trials phases I, II or III for new diagnostic techniques
Clinical guidelines for the general population (prevention)
Dependent variables: medical innovation categories
We asked respondents to report how often they participated in any of the following 
activities during the year 2012. 
Responses could range from 0 (never) to more than 10 times.
Categories
DV 1: Commercialization
DV 2: New drug development
DV 3: Clinical guidelines
DV 4: Diagnostics and prevention
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 Factor analysis showed the existence of four categories / forms of medical innovation
 DVs: frequency in which scientists have participated in any of the activities listed in 
each category
Independent variables: brokerage roles
We followed an ego-centric network approach (e.g.: Baer, 2010; Smith et al., 2005) to capture
each scientist’ personal network structure and composition.
 Personal network size:
Respondents were asked to write down the names of those persons (up to ten)
from outside their research group that were of critical importance for the
advancement of their research activities.
 Personal network composition:
Respondents were asked to classify each of the contacts previously mentioned into any
of the following professional groups: 1=basic scientists, 2=clinical scientists, 3=medical
practitioners / patient representatives, 4=public administration, industry / other.
 Personal network structure: 
Respondents were presented an alter-alter matrix and were asked to report whether the 
set of contacts previously mentioned know each other.
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Independent variables: brokerage roles
 Personal network structure and content allowed us to compute the brokerage roles.
 We followed Gould and Fernandez (1989) procedure to count separately the number
of times each scientist is playing any of the four brokerage roles, based on the
afﬁliations of the three nodes involved in the triadic relationship.
 The same scientist can simultaneously play different brokerage roles. Example:
Basic scientist
Clinical scientist
Firm employee
Focal scientist is a clinical scientist with 6 direct contacts
He plays 12 brokerage roles:
Coordinator: n=1 (4-6)
Consultant: n=2 (5-3; 1-2)
Gatekeeper n=7 (4-5; 4-3; 4-1; 6-1; 6-2; 6-3; 6-5) 
Liaison: n=2 (5-1; 2-3)
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Frequency of brokerage roles
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 Most of the scientists do not play any brokerage role at all.
 Coordinator is the most frequent role. 
 Being a liaison is particularly rare
 Different brokerage positions are weakly correlated between them 16
Control variables and econometric model
• Individual level:
• Age
• Gender
• Academic position 
• External network size
• Group and Institutional level:
• Research team’s size
• Institutional affiliation: University, Hospital, PROs and Others
• Type of CIBER
• Research teams’ past scientific performance
• Research teams’ past technological performance
• Econometric model
• Our DVs are a count of scores, suggesting the use of a count model.
• DV is skewed. We used a negative binomial regression 
• Robustness check with Poisson and OLS 
17
Main variables Commercialization Drug development Clinical guidelines
Diagnostics & 
prevention
Liaison 0.049* -0.021 0.037 0.048*
(0.03) (0.04) (0.03) (0.03)
Gatekeeper 0.047** 0.047** 0.041 0.055***
(0.02) (0.02) (0.03) (0.02)
Consultant 0.009 0.004 -0.021 -0.024
(0.02) (0.03) (0.03) (0.03)
Coordinator -0.017 -0.069*** -0.013 -0.061***
(0.02) (0.02) (0.03) (0.02)
Observations 1094 1095 1095 1095
Pseudo – R2 0.113 0.0864 0.0738 0.0496
* p < 0.1,  ** p < 0.05,  *** p < 0.01
Control variables: age, academic position, group size, institution type, CIBER, affiliation type, ego-network
size, gender, group scientific performance, group technological performance
Preliminary results: brokerage roles and medical innovation
H1
Gatekeeper is positively 
related to 3 of 4 
innovation categories
18
Negative effect of being a 
coordinator
Hospital Non – hospital
Main variables Commercializ.
Drug
development
Clinical
guidelines
Diagnostics & 
prevention Commercializ.
Drug
development
Clinical 
guidelines
Diagnostics & 
prevention
Liaison 0.063** 0.007 0.049 0.048 -0.004 -0.074 0.047 0.055
(0.03) (0.06) (0.03) (0.04) (0.07) (0.07) (0.07) (0.04)
Gatekeeper -0.028 0.059* -0.002 0.075** 0.068** 0.057 0.081** 0.053**
(0.03) (0.03) (0.03) (0.03) (0.03) (0.04) (0.04) (0.03)
Consultant 0.036 -0.052 -0.006 0.051 0.008 0.029 -0.044 -0.076**
(0.04) (0.04) (0.04) (0.06) (0.03) (0.06) (0.04) (0.03)
Coordinator -0.011 -0.026 0.017 -0.084** -0.019 -0.119*** -0.007 -0.044*
(0.04) (0.03) (0.02) (0.04) (0.02) (0.04) (0.04) (0.02)
Observations 396 397 397 397 698 698 698 698
Pseudo R2 0.144 0.0683 0.0837 0.102 0.131 0.0801 0.0795 0.0630
• p < 0.1,  ** p < 0.05,  *** p < 0.01
Preliminary results: distinctive effects in hospital / non-hospital settings
Split sample analysis. Scientists working at hospitals (n=397) vs scientists not working at 
hospitals (n=698)
Econometric model: negative binomial regression
H2
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Wald tests show significant differences on the predictive power of gatekeepers in both contexts.
Being a gatekeeper is particularly important in non-hospital settings as a facilitator of the participation in medical innovation
Contributions and preliminary conclusions
 We provide empirical evidence on the relevance of brokerage to facilitate medical
innovation. Existing research has been prescriptive or qualitative (e.g.: Currie & White, 2012,
Waring et al., 2013).
 We adopted the Gould and Fernandez (1989) classification of brokerage types to
count the frequency of scientists holding liaison, gatekeeper, consultant and coordinator
positions.
 We emphasized the trade-off of benefits and costs of holding brokerage positions.
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Contributions and preliminary conclusions (ii)
 We found that the positive effects of brokerage is not that evident if the distinction
between brokerage roles is considered: gatekeeper provides the greater advantage.
 We found that being a coordinator may have negative effects on the scientists’ propensity
to participate in medical innovation.
 We found that the benefits of gatekeeper positions operate differently in hospital and non-
hospital settings, showing evidence of its critical importance for non-hospital scientists.
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Mean SD Min Max
Commercialization 0.267 1.133 0 28
Drug development 0.562 1.759 0 22
Clinical guidelines 0.514 1.392 0 14
Diagnostics and prevention 0.328 1.284 0 30
Liaison 0.483 1.871 0 27
Gatekeeper 2.265 4.500 0 25
Consultant 0.940 2.971 0 32
Coordinator 2.259 5.050 0 45
Large ego-network size 0.310 0.463 0 1
Age 41.894 10.651 23 78
Academic position 3.029 1.316 1 6
Group size 18.248 10.457 2 79
Institution type 2.050 0.874 1 4
CIBER 4.581 2.573 1 9
Affiliation type 1.850 0.511 1 3
Ego-network size < 2 0.265 0.442 0 1
Gender 1.531 0.499 1 2
Group scientific performance 53.943 46.351 3 295
Group technological performance 1.002 2.248 0 21
Descriptive statistics
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Dependent variables: medical innovation categories
Mean SD Min Max
DV 1: Commercialization 0.267 1.133 0 28
DV 2: Drug development 0.562 1.759 0 22
DV 3: Clinical guidelines 0.514 1.392 0 14
DV 4: Diagnostics and 
prevention 0.328 1.284 0 30
 Factor analysis revealed the existence of four distinct categories of medical innovation 
activities.
 Dependent variables: count of the frequency each scientist has been engaged in any
the activities of each category.
 Because they are count of scores, variables take on non-negative integer values
 We selected a negative binomial model to adress the overdispersion and the
prevalence of 0 counts in the DVs.
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Preliminary results: distinctive effects in hospital / non-hospital 
settings
We performed four Wald tests to take account of the covariance in the parameters across
the two models (hospitals vs non-hospitals). We compared the coefficients of Liaison,
Gatekeeper, Consultant and Coordinator in both models and for our four dependent
variables.
We found that:
 Occupying gatekeeper positions is particularly important among non-hospital
settings as an antecedent to their participation in medical innovation activities.
 Occupying liaison positions is particularly important for hospital scientists to
facilitate their engagement in commercialization activities.
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